Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 3.220
+0.070 (2.22%)
Jun 19, 2026, 4:25 PM CET
Nykode Therapeutics AS Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Nykode Therapeutics AS stock has a consensus rating of "Strong Buy" and an average price target of kr 5.00. The average 1-year stock price forecast is 55.28% higher than the current stock price, while the lowest is kr 4.50 (+39.75%) and the highest is kr 5.50 (+70.81%).
Price Target: kr 5.00 (+55.28%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nykode Therapeutics AS stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Dec '25 | Jan '26 | Mar '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 0 | 1 | 1 | 2 |
Financial Forecast
Revenue This Year
n/a
from 453.00K
Decreased by -100.00%
Revenue Next Year
16.93M
EPS This Year
-0.07
from -0.04
EPS Next Year
-0.01
from -0.07
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | ||
| Avg | n/a | ||
| Low | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -100.0% | ||
| Avg | -100.0% | ||
| Low | -100.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | -0.07 | ||
| Low | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |